Starling Oncology, Inc.
STLN- Exchange
- Nasdaq
- Industry
- Services-Offices & Clinics of Doctors of Medicine
- SEC CIK
- 0001799191
In the last 90 days, Starling Oncology, Inc. insiders filed 3 open-market purchases and 2 sales; 119 institutions reported holding it in 13F filings for Q2 2026, worth $217.6M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Starling Oncology, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 1 | 21 | +20 |
| Shares | 252.4K | 21.1M | +20.9M (+8,265.6%) |
| Value | $2.50M | $199.9M | +$197.4M (+7,882.5%) |
New holders (21)
Institutions that held Starling Oncology, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FMR LLC | 12,000,000 | $111.2M | 0.01% |
| Deerfield Management Company, L.P. (Series C) | 3,296,107 | $32.1M | 0.68% |
| Redmile Group, LLC | 2,500,000 | $24.4M | 0.55% |
| Velan Capital Investment Management LP | 600,000 | $5.85M | 4.89% |
| Parian Global Management LP | 466,676 | $4.55M | 4.12% |
| Vanguard Group Inc | 442,344 | $4.31M | 0.00% |
| Hongkou Capital LP | 400,000 | $3.90M | 3.86% |
| Alpine Global Management, LLC | 384,988 | $3.75M | 0.56% |
| Saba Capital Management, L.P. | 400,000 | $3.73M | 0.08% |
| Empery Asset Management, LP | 200,000 | $1.95M | 4.07% |
| CVI Holdings, LLC | 200,000 | $1.95M | 0.13% |
| Goldman Sachs Group Inc | 116,098 | $1.13M | 0.00% |
| Citadel Advisors LLC | 39,561 | $386.0K | 0.00% |
| ExodusPoint Capital Management, LP | 30,700 | $299.0K | 0.00% |
| Qube Research & Technologies Ltd | 18,688 | $182.0K | 0.00% |
| Geode Capital Management, LLC | 11,147 | $108.0K | 0.00% |
| Penserra Capital Management LLC | 5,038 | $49.0K | 0.00% |
| JPMorgan Chase & Co | 3,800 | $37.0K | 0.00% |
| UBS Group AG | 1,859 | $18.0K | 0.00% |
| Morgan Stanley | 932 | $9.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 200 | $2.00K | 0.00% |
Sold out (1)
Institutions that held Starling Oncology, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace, LLP | 252,439 | $2.50M |